Recce Pharmaceuticals Advances Phase 3 Trial in Indonesia

Recce Pharmaceuticals Ltd. (AU:RCE) has released an update.

Recce Pharmaceuticals has received approval from Indonesia’s Drug and Food Authority to launch a Phase 3 clinical trial of its RECCE 327 topical gel for diabetic foot infections, marking a significant step towards commercialization and enhanced healthcare options in the region. This trial, set to be one of the largest of its kind, will involve up to 300 patients and is expected to bring near-term revenue opportunities in the ASEAN market. The initiative, supported by key stakeholders, underscores Recce’s growth trajectory and commitment to addressing critical health challenges.

For further insights into AU:RCE stock, check out TipRanks’ Stock Analysis page.